Intra Cellular Therapies Alpha and Beta Analysis
| ITCIDelisted Stock | USD 131.87 0.03 0.02% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Intra Cellular Therapies. It also helps investors analyze the systematic and unsystematic risks associated with investing in Intra Cellular over a specified time horizon. Remember, high Intra Cellular's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Intra Cellular's market risk premium analysis include:
Beta (0.64) | Alpha 0.8 | Risk 0.0 | Sharpe Ratio 0.0 | Expected Return 0.0 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Intra |
Intra Cellular Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Intra Cellular market risk premium is the additional return an investor will receive from holding Intra Cellular long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Intra Cellular. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Intra Cellular's performance over market.| α | 0.80 | β | -0.64 |
Intra Cellular Fundamentals Vs Peers
Comparing Intra Cellular's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Intra Cellular's direct or indirect competition across all of the common fundamentals between Intra Cellular and the related equities. This way, we can detect undervalued stocks with similar characteristics as Intra Cellular or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Intra Cellular's fundamental indicators could also be used in its relative valuation, which is a method of valuing Intra Cellular by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Intra Cellular to competition |
| Fundamentals | Intra Cellular | Peer Average |
| Return On Equity | -0.0858 | -0.31 |
| Return On Asset | -0.0696 | -0.14 |
| Profit Margin | (0.11) % | (1.27) % |
| Operating Margin | (0.15) % | (5.51) % |
| Current Valuation | 13.06 B | 16.62 B |
| Shares Outstanding | 106.52 M | 571.82 M |
| Shares Owned By Insiders | 2.48 % | 10.09 % |
Intra Cellular Opportunities
Intra Cellular Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Sanjeev Narula of 22727 shares of Intracellular subject to Rule 16b-3 | 02/03/2025 |
2 | Intra-Cellular Therapies GAAP EPS of -0.16 misses by 0.04, revenue of 199.22M beats by 5.93M | 02/21/2025 |
3 | Acquisition by Mark Neumann of 18714 shares of Intracellular at 36.89 subject to Rule 16b-3 | 03/03/2025 |
4 | Is Intra-Cellular Therapies, Inc. a Best Biotech Stock According to Billionaires | 03/17/2025 |
5 | Deep Track Capital, LP Acquires Significant Stake in Dianthus Therapeutics Inc | 03/24/2025 |
6 | Beam Therapeutics Down 21.4 percent Since Last Earnings Report Can It Rebound | 03/27/2025 |
7 | Johnson Johnson Announces Completion Timeline for Intra-Cellular Therapies Acquisition | 04/01/2025 |
About Intra Cellular Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Intra or other delisted stocks. Alpha measures the amount that position in Intra Cellular Therapies has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Intra Cellular Upcoming Company Events
As portrayed in its financial statements, the presentation of Intra Cellular's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Intra Cellular's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Intra Cellular's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Intra Cellular. Please utilize our Beneish M Score to check the likelihood of Intra Cellular's management manipulating its earnings.
| 6th of March 2024 Upcoming Quarterly Report | View | |
| 2nd of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 6th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Intra Cellular
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in banks. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Intra Stock
If you are still planning to invest in Intra Cellular Therapies check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intra Cellular's history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |